Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

The combination of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir is a potent, once-daily therapy indicated for the treatment of chronic HCV infection in individuals coinfected with human immunodeficiency virus (HIV). We e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Feng, Hwa-Ping, Caro, Luzelena, Fandozzi, Christine, Chu, Xiaoyan, Guo, Zifang, Talaty, Jennifer, Panebianco, Deborah, Dunnington, Katherine, Du, Lihong, Hanley, William D., Fraser, Iain P., Mitselos, Anna, Denef, Jean-Francois, De Lepeleire, Inge, de Hoon, Jan N., Vandermeulen, Corinne, Marshall, William L., Jumes, Patricia, Huang, Xiaobi, Martinho, Monika, Valesky, Robert, Butterton, Joan R., Iwamoto, Marian, Yeh, Wendy W.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437487/
https://ncbi.nlm.nih.gov/pubmed/30745392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02142-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados